Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 09 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Nitroglycerin Sublingual Tablets. These tablets are used to relieve chest pain in patients with coronary artery disease and will be manufactured at the company's facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases